Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051492 | 0.81 | KMT2A (0.56) | SMN1; SMN2KDM4ENPC1ALOX15RAB9A | |
| SCHEMBL18381247 | 0.79 | KMT2A (0.60) | SMN1; SMN2NPC1ALOX15RAB9AKMT2A | |
| SCHEMBL19051491 | 0.78 | RAB9A (0.55) | SMN1; SMN2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL21820359 | 0.77 | RAB9A (0.46) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL17473831 | 0.76 | MMP9 (0.35) | SMN1; SMN2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL21820172 | 0.76 | CNR1 (0.36) | SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10674362 | 0.76 | KDM4E (0.67) | SMN1; SMN2KDM4ENPC1ALOX15RAB9A | |
| SCHEMBL17473828 | 0.75 | ST14 (0.36) | SMN1; SMN2RAB9AKMT2AMEN1HPGD | |
| SCHEMBL13734799 | 0.75 | MAPT (0.33) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1300262 | 0.73 | MAPT (0.52) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | SMN1; SMN2 4557/4885KDM4E 1532/4885NPC1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.